Abstract
The level of expression of midkine (MK), a heparin-binding growth factor, is increased in many types of human carcinomas. An enzyme-linked immunoassay, which utilizes a combination of rabbit and chicken antibodies revealed that serum MK level in the controls (n= 135) was 0.154 ± 0.076 (mean ± SD) ng ml–1with an apparent cut-off value as 0.5 ng ml–1. Serum MK level was significantly elevated in the cancer patients (n= 150) (P< 0.001); 87% of the patients showed levels of more than 0.5 ng ml–1. All ten types of cancer examined showed a similar profile of serum MK level. There was no or weak correlation between C-reactive protein level, a marker of inflammation, and serum MK level. Furthermore, in case of gastric carcinoma and lung carcinoma, patients with stage I carcinoma already showed elevated serum MK levels. The present results indicated that serum MK could serve as a general tumour marker with a good potential for clinical application. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T and Muramatsu T (1995) Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 86: 655–661
Choudhuri R, Zhang HT, Donnini S, Ziche M and Bicknell R (1997) An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 1814–1819
Garver RI Jr, Radford DM, Donis-Keller H, Wick MR and Milner PG (1994) Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74: 1584–1590
Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikemastu S, Sakuma S, Hayashi K, Yuzawa Y, Matsuo S, Kuzuya M, Kaname T, Hirai M, Saito H and Muramastu T (2000) Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 105: 489–495
Ishikawa E, Yoshitake S, Imagawa M and Sumiyoshi A (1993) Preparation of monomeric Fab’-horseradish peroxidase conjugate using thiol groups in the hinge and its evaluation in enzyme immunoassay and immunohistochemical staining. Ann NY Acad Sci 420: 74–89
Kadomatsu K, Tomomura M and Muramatsu T (1988) cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 151: 1312–1318
Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H and Muramatsu T (1997) Midkine induces the transformation of NIH3T3 cells. Br J Cancer 75: 354–359
Kojima S, Muramatsu H, Amanuma H and Muramatsu T (1995) Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 270: 9590–9596
Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao Y, Muramatsu T and Kadomatsu K (1999) Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 57: 253–257
Kurtz A, Schulte AM and Wellstein A (1995) Pleiotrophin and midkine in normal development and tumour biology. Crit Rev Oncog 6: 151–177
Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, Milbrandt J and Deuel TF (1990) Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 250: 1690–1694
Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T and Noda M (1999) A receptor-like protein tyrosine phosphatase (PTP ζ /RPTP β) binds a heparin binding growth factor midkine: Involvement of arginine 78 of midkine in the high affinity binding to PTP ζ. J Biol Chem 274: 12474–12479
Meremies J and Rauvala H (1990) Molecular cloning of the 18-kDa growth-associated protein of developing brain. J Biol Chem 265: 16721–16724
Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T and Kim SU (1993) Retinoic acid responsive gene product, midkine (MK), has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res 35: 530–539
Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, Muramatsu T and Kurino T (1997) Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 233: 29–32
Muramatsu H, Shirahama H, Yonezawa S, Maruta H and Muramatsu T (1993) Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 159: 392–402
Muramatsu H, Song XJ, Koide N, Hada H, Tsuji T, Kadomatsu K, Inui T, Kimura T, Sakakibara S and Muramatsu T (1996) Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. J Biochem 119: 1171–1175
Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A and Brodeur GM (1995) Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 55: 1792–1797
Owada K, Saijo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T and Michikawa M (1999) Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidyl-inositol 3-kinase in cultured neurons. J Neurochem 73: 2084–2092
O’Brien T, Cranston D, Fuggle S, Bicknell R and Harris AL (1996) The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56: 2515–2518
Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T and Kadomatsu K (2000) Midkine rescues Wilms’ tumour cells from cisplatin-induced apoptpsis: regulation of Bcl-2 expression by midkine. J Biochem 127: 269–277
Raulais D, Lagente-Chevallier O, Guettet C, Duprez D, Courtois Y and Vigny M (1991) A new heparin-binding protein regulated by retinoic acid from chick embryos. Biochem Biophys Res Commun 174: 708–715
Song XJ, Muramatsu H, Aridome K, Aikou T, Koide N, Tsuji T and Muramatsu T (1997) The serum level of midkine, a heparin-binding growth factor, as a tumour marker. Biomed Res 18: 375–381
Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S and Muramatsu T (1997) Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 122: 453–458
Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, Shimazu H, Ohi Y and Muramatsu T (1993) A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumour and other human carcinomas. Cancer Res 53: 1281–1285
Ye C, Qi M, Fan QW, Ito K, Akiyama S, Kasai Y, Matsuyama M, Muramatsu T and Kadomatsu K (1999) Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 79: 179–184
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ikematsu, S., Yano, A., Aridome, K. et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 83, 701–706 (2000). https://doi.org/10.1054/bjoc.2000.1339
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1339
Keywords
This article is cited by
-
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease
Translational Neurodegeneration (2023)
-
Curcumin: a natural organic component that plays a multi-faceted role in ovarian cancer
Journal of Ovarian Research (2023)
-
Diagnostic performance of Midkine ratios in fine-needle aspirates for evaluation of Cytologically indeterminate thyroid nodules
Diagnostic Pathology (2021)
-
Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer
Scientific Reports (2021)
-
Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target
Oncogene (2020)